|
|
Blood, Vol. 114, Issue 3, 511-517, July 16, 2009
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
Blood Alousi et al.
114: 511
Supplemental materials for: Alousi et al
Participating institutions and co-investigators for the BMTCTN 0302 study were MD Anderson Cancer Research Center (Amin M. Alousi, M.D., N=26), Johns Hopkins University (Javier Bolanos-Meade, M.D., N=23), University of Minnesota (Daniel Weisdorf, M.D., N=23), Dana Farber Brigham Women’s Partners (Vincent Ho, M.D., N=16), University of Michigan Medical Center (John Levine, M.D., N=13), Oregon Health Sciences University (Eneida Nemecek, M.D., N=10), University of Florida College of Medicine (John Wingard, M.D., N=10), University of Pennsylvania Hospital Center (Steven Goldstein, M.D., and Edward Stadtmauer, M.D., N=10), University of Nebraska Medical Center (Marcel Devetten, M.D., N=7), Washington University of St. Louis (John DiPersio, M.D., and Peter Westervelt, M.D., N=7), Stanford Hospital and Clinics (Laura Johnston, M.D., N=6), University of California at San Diego (Edward Ball, M.D., N=6), Duke University Medical Center (Nelson Chao, M.D., and Joanne Kurtzberg, M.D., N=5), University Hospitals of Cleveland (CWRU) (Hillard Lazarus, M.D., N=5), Memorial Sloan-Kettering Cancer Center (Nancy Kernan, M.D., and Miguel-Angel Perales, M.D., N=4), Texas Transplant Institute (Carlos Bachier, M.D., Michael Grimley, M.D., and Paul Shaughnessy, M.D., N=4), City of Hope National Medical Center (Pablo Parker, M.D., N=2), Fred Hutchinson Cancer Research Center (Richard Nash, M.D., N=2), and Hackensack University Medical Center (Joel Brochstein, M.D., N=1).
|
|
